WallStSmart

Accuray Incorporated (ARAY)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 4620% more annual revenue ($20.63B vs $436.97M). GEHC leads profitability with a 10.1% profit margin vs -8.2%. GEHC appears more attractively valued with a PEG of 1.70. GEHC earns a higher WallStSmart Score of 60/100 (C+).

ARAY

Hold

44

out of 100

Grade: D

Growth: 4.7Profit: 2.5Value: 4.0Quality: 3.5
Piotroski: 5/9Altman Z: -0.03

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ARAY.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARAY2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.8%8/10

16.8% revenue growth

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

ARAY4 concerns · Avg: 2.5/10
Market CapQuality
$45.86M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.7%3/10

Operating margin of 3.7%

PEG RatioValuation
29.492/10

Expensive relative to growth rate

Return on EquityProfitability
-70.3%2/10

ROE of -70.3% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ARAY

The strongest argument for ARAY centers on Price/Book, Revenue Growth. Revenue growth of 16.8% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : ARAY

The primary concerns for ARAY are Market Cap, Operating Margin, PEG Ratio. Debt-to-equity of 3.83 is elevated, increasing financial risk.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ARAY profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

ARAY carries more volatility with a beta of 1.20 — expect wider price swings.

ARAY is growing revenue faster at 16.8% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Accuray Incorporated

HEALTHCARE · MEDICAL DEVICES · USA

Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?